Parkinson’s Progressive Marker Initiative PPMI - (still enrolling)
Parkinson’s Progression Markers Initiative is The Michael J. Fox Foundation's flagship biomarkers study seeking to learn more about the genetics of Parkinson's disease (PD). PPMI is currently studying the connection between PD and having a mutation in either the LRRK2 or GBA gene — both are promising targets of PD research.
What’s involved: Participants will be seen for periodic exams and clinical tests for up to 5 years.
Eligible patients will:
- Be of Eastern European (Ashkenazi) Jewish, North African Berber, or Basque Ancestry.
- Have a diagnosis of PD or be related to someone with PD who is of Eastern European (Ashkenazi) Jewish, North African Berber, or Basque Ancestry.
- Complete initial screening through the MJFF program
To learn more: Contact Zoran Obradov (623) 832-6526 to ask about the PPMI study.
SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study
Research Study Goal: To assess the safety and efficacy of the investigational drug SYN120 in patients with Parkinson’s disease dementia (PDD) already treated with a stable dose of a cholinesterase inhibitor.
What’s involved: patients will have a 50 percent chance of receiving placebo or SYN120. This study includes a screening period of up to 6 weeks, a 16-week treatment period, and a 2-week safety follow up period.
- Are at least 50 years of age
- Have a diagnosis of Parkinson’s disease and dementia
- Have been taking a stable dose of Aricept (donepezil), Exelon (rivastigmine), or Razadyne (galantamine) for at least 12 weeks.
To learn more: Contact Christina Chong (623) 832-6512.
Study of Urate Elevation in Parkinson’s Disease-Phase 3 (SURE-PD3)
Study Goal: To determine whether inosine dosed to moderately elevate uric acid levels slows the progression of Parkinson disease over a 2-year period.
What’s Involved: Patients will have a 50 percent chance of receiving active treatment or a placebo. They will complete regular study exams and blood tests over a 2-year period.
- Have a diagnosis of PD made in the past 3 years
- Are at least 30 years old
- Are not taking medication for PD other than Azilect or selegiline
- Do not have gout, congestive heart failure, COPD, or history of heart attack or stroke
- No history of uric acid or urate urolithiasis, or recurrent urolithiasis all of unknown type.
To learn more: Contact Molly Goddard (623) 832-5726.
Study of NBI-98854 in Children and Adolescents with Tourette Syndrome
Study Goal: To determine whether NBI-99854 is safe and well-tolerated, and reduces tic symptoms in children with Tourette syndrome
What’s Involved: Patients will have a 50 percent chance of receiving active investigational treatment or a placebo (an inactive substance). They will complete regular study exams over an 8 week period. At the end of the eight weeks, eligible participants will be offered an opportunity to join an additional study on long term safety and effectiveness of NBI-98854 (where all participants receive the active study medication). View a video about this study.
- Have a diagnosis of Tourette syndrome
- Have at least moderate severity of tics
- Have tics that interfere with school, work or social activities
- Are in good general health
Do not have a history of drug or alcohol dependence
To learn more: Contact Molly Goddard 623-832-5726.
Biogen (actively recruiting)
The purpose of the study is to find out whether the study medication has the potential to be a helpful treatment that slows down disease progression in subjects with early Alzheimer’s disease by comparing it to placebo, to evaluate its safety (side effects), and to find out more about the study medication. Ages 50-85.
USC A4 LZAZ (actively recruiting healthy volunteers)
The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the “A4 study”) is a clinical trial for older individuals who may be at risk for Alzheimer’s disease memory loss.
The A4 study is testing an anti-amyloid investigational drug in older individuals who have evidence of elevated amyloid build-up in their brains, but who do not show symptoms of AD in order to slow possible AD-related damage in the brain and to delay progression of AD-related memory loss.
The purpose of this study is to test whether an investigational drug can slow the progression of memory problems associated with brain amyloid.
To qualify: Age of 65-85 with no history of or complaint of memory problems.
Astra Zeneca AMARANTH study
The purpose of this study is to see if the drug AZD3293 is effective and safe in treating early Alzheimer’s disease compared with placebo.
To qualify: Age 55-85 with a diagnosis of Mild Cognitive Impairment or early Alzheimer’s disease.
The HEADWAY-DLB Study
Study Goal: To determine if RVT-101 is safe and shows promise of improving symptoms of Dementia with Lewy bodies (DLB).
What’s Involved: Patients will have a 1 in 3 chance of receiving placebo and 2 in 3 chance of receiving one of two different doses of RVT-101. They will complete serial exams and cognitive testing over a 24 week period.
- Have a diagnosis of DLB or Lewy body dementia, where the memory or thinking problems clearly began in the first year of symptoms.
- Are not too advanced in their dementia to complete cognitive testing that involves speaking and writing.
- Have a reliable caregiver that can report on his/her status at every study visit
- Are not seriously ill with another condition that could interrupt participation in the study
To learn more: Contact Christina Chong at (623) 832-6512.